Abstract
Background: Carcinoembryonic antigen (CEA) is the most common serum tumor marker in colorectal cancer (CRC). Nevertheless, few previous studies demonstrated the impacts of postoperative CEA and post-preoperative CEA increment on prognosis of CRC. Methods: Patients with stage II and III CRC were included from January 2009 to December 2015. All clinical and follow-up data were collected. Patients were divided into four different groups according to the levels of postoperative serum CEA and post-preoperative CEA trends. Chi-square test was used to analyze the relationship between clinical variables and categorized postoperative CEA and CEA increment. Cox proportional hazard regression was used for univariate and multivariable analyses. The log-rank test was performed to compare PFS and OS among groups. Results: Patients, 1,008, who underwent radical surgery, were enrolled. Our results showed that positive postoperative CEA and CEA increment were related to clinical stage, T stage, N stage, tumor differentiation, and lymphatic invasion (p < 0.05). Univariate and multivariable analysis results suggested that positive postoperative CEA and CEA increment were independent prognostic factors for PFS (HR = 3.149, 95% CI, 2.426-4.088, p =...Continue Reading
References
Oct 25, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gershon Y LockerUNKNOWN ASCO
Oct 29, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A S StrimpakosI Chau
Feb 2, 2010·Journal of Surgical Oncology·Jung Wook HuhYoung Jin Kim
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R LabiancaUNKNOWN ESMO Guidelines Working Group
Nov 26, 2010·Surgical Oncology·Won-Suk LeeYeon Ho Park
May 4, 2011·International Journal of Colorectal Disease·Jen-Kou LinShih-Ching Chang
Jun 28, 2012·British Journal of Cancer·I TarantinoU Güller
Mar 5, 2013·Radiation Oncology·Kai-Lin YangLing-Wei Wang
Jul 16, 2013·International Journal of Cancer. Journal International Du Cancer·M J DuffyC Sturgeon
Jan 17, 2014·JAMA : the Journal of the American Medical Association·John N PrimroseUNKNOWN FACS Trial Investigators
Feb 8, 2014·Surgery Today·Tsukasa HottaHiroki Yamaue
Feb 15, 2014·American Journal of Surgery·Chih-Sheng HuangShih-Ching Chang
Jan 15, 2015·Annals of Surgical Oncology·Raphael L C AraujoYuman Fong
Mar 17, 2015·International Journal of Surgery·Imran BhattiGiuseppe Garcea
Dec 15, 2015·The Cochrane Database of Systematic Reviews·Brian D NicholsonDavid Mant
Jan 26, 2016·CA: a Cancer Journal for Clinicians·Wanqing ChenJie He
Jun 5, 2016·Oncology·Gota SaitoAkemi Kamijo
Oct 30, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S LonardiUNKNOWN TOSCA (Three or Six Colon Adjuvant) Investigators
Mar 2, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Apr 17, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Takayuki YoshinoJosep Tabernero
Dec 23, 2017·JAMA Oncology·Tsuyoshi KonishiMartin R Weiser
Apr 6, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thierry AndréUNKNOWN for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER
Apr 11, 2018·Journal of the National Comprehensive Cancer Network : JNCCN·Al B BensonDeborah A Freedman-Cass
Jun 7, 2018·British Journal of Cancer·Maria ThomsenTormod Kyrre Guren
Jul 15, 2018·Journal of the National Comprehensive Cancer Network : JNCCN·Al B BensonDeborah A Freedman-Cass
Jul 20, 2019·Molecular Oncology·Elena ElezAna Vivancos
Jul 25, 2019·Journal of Cancer·Weiqiang YouZhigang Wang
Oct 22, 2019·Lancet·Evelien DekkerMichael B Wallace
Dec 5, 2019·Cancer Medicine·Yuya NakamuraYukihide Kanemitsu
Jul 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R Glynne-JonesUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org